Susquehanna maintains a Positive rating on SciClone Pharmaceuticals (Nasdaq: SCLN). Price target $2.50.

Susquehanna analyst says, "In the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE